OTL–101 (Orchard Therapeutics)

OTL–101
(Orchard Therapeutics)

Primary immune deficiency (Metabolic disorder)
Phase III

OTL–101

This is a partner's product, where Oxford Biomedica provide process development and bioprocessing. For more information on Orchard Therapeutics products their website.